NEUROTROPE, INC. (OTCMKTS:NTRPD) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02
On February 17, 2017, upon the recommendation of the Nominating and Governance Committee of the board of directors (the “Board”) of Neurotrope, Inc. (the “Company”), the Board appointed Andrew D. Perlman as a member of the Board, effective immediately, to hold office until the next annual meeting of the stockholders of the Company, until his successor is duly elected and qualified, or until his resignation or removal. Effective February 17, 2017, Mr. Perlman was appointed to serve as a member of the Audit Committee of the Board. Consistent with the Company’s standard compensation arrangements for non-employee directors, Mr. Perlman will receive an option to purchase, at an exercise price equal to the price at which the Company’s common stock closes on February 17, 2017, as reported by the OTCQB, up to (i) 7,813 shares of the Company’s common stock for his service to the Company as a non-employee director and (ii) 1,563 shares of the Company’s common stock for his service to the Company as a committee member, each such grant to vest in equal daily installments over a five-year period beginning on the date of grant. The options are granted subject to stock option agreements to be entered into by and between the Company and Mr. Perlman evidencing the granting of the options, substantially in the form of the Company’s standard form of stock option. There are no arrangements or understandings between Mr. Perlman and any other person to which he was selected as a director. The Company is not aware of any transaction in which Mr. Perlman has an interest requiring disclosure under Item 404(a) of Regulation S-K.
About NEUROTROPE, INC. (OTCMKTS:NTRPD)
Neurotrope, Inc., formerly BlueFlash Communications, Inc., is a biopharmaceutical company with its product candidates in pre-clinical and clinical development. The Company is focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer’s disease (AD), which is in the clinical testing stage. Bryostatin, which is a protein kinase C (PKC) Alpha and e activator, is also developed for other neurodegenerative or cognitive diseases and dysfunctions, which are in pre-clinical testing. Its second generation PKC activators, such as the Bryologs are meant for the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection and traumatic brain injury. It develops Bryostatin-1 for the treatment of Alzheimer’s disease along with the rare (Orphan) diseases, such as Fragile X Syndrome and Niemann-Pick Type C. It has completed Phase IIa clinical trials of Bryostatin-1 for the treatment of patients with AD. NEUROTROPE, INC. (OTCMKTS:NTRPD) Recent Trading Information
NEUROTROPE, INC. (OTCMKTS:NTRPD) closed its last trading session down -0.14 at 18.33 with 98,051 shares trading hands.
